Publications by authors named "Michelle Carlsen"

Claim this Profile
R
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated -Mutated Metastatic NSCLC.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio, Michelle Carlsen

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated -Mutated Metastatic NSCLC: RELAY Japanese Subset.
Makoto Nishio, Takashi Seto, Martin Reck, Edward B Garon, Kazuto Nishio, Michelle Carlsen

JTO Clin Res Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RELAY, Erlotinib Plus Ramucirumab in Untreated, -Mutated, Metastatic NSCLC: Outcomes by Exon 19 Deletion Variants.
Kazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, Martin Reck, Edward B Garon, Michelle Carlsen

JTO Clin Res Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with -activating mutations (RELAY phase 3 randomized study).
Kazuto Nishio, Kazuko Sakai, Makoto Nishio, Takashi Seto, Carla Visseren-Grul, Michelle Carlsen

Transl Lung Cancer Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implantation of telemetric blood pressure transmitters in Göttingen Minipigs: Validation of 24-h systemic blood pressure and heart rate monitoring and influence of anaesthesia.
Michelle Fischer Carlsen, Berit Østergaard Christoffersen, Rikke Lindgaard, Henrik Duelund Pedersen, Lisbeth Høier Olsen

J Pharmacol Toxicol Methods· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Antoine Hollebecque, Hyun C Chung, Maria J de Miguel, Antoine Italiano, Jean-Pascal Machiels, Michelle Carlsen

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Afshin Dowlati, R Donald Harvey, Richard D Carvajal, Omid Hamid, Samuel J Klempner, Michelle Carlsen

Invest New Drugs· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, Maria J de Miguel, Yung-Jue Bang, Michelle Carlsen

Clin Cancer Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study.
Karen A Autio, Christopher A Klebanoff, David Schaer, John Sae Wook Kauh, Susan F Slovin, Michelle Carlsen

Clin Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Linkage Disequilibrium for Ultrahigh-Dimensional Genome-Wide Data with an Integrated Statistical Approach.
Michelle Carlsen, Guifang Fu, Shaun Bushman, Christopher Corcoran

Genetics· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis